# AZD9750

Source: https://onco.cc/drugs/azd9750/  
OnCo record `azd9750` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AZD9750 is an experimental protein degrader from AstraZeneca in phase 2 trials for prostate cancer, aimed at Androgen receptor.

## Summary

AZD9750 is a protein degrader developed by AstraZeneca. Its target is Androgen receptor (the sponsor names androgen receptor (AR)). The sponsor states: An AR-PROTAC that binds the androgen receptor and recruits it for proteasomal degradation, rather than simply inhibiting its function. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in prostate cancer. The largest, NCT07336446, plans to enrol 300 participants with primary completion expected 2029-01-26. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: protein degrader
- Mechanism: An AR-PROTAC that binds the androgen receptor and recruits it for proteasomal degradation, rather than simply inhibiting its function.

## Sources

- ClinicalTrials.gov: trials of AZD9750: https://clinicaltrials.gov/search?intr=AZD9750

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs](https://onco.cc/trials/nct07336446/)

---
JSON: https://onco.cc/api/v1/entities/azd9750.json